EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

SHR ‐2004, a Humanized Monoclonal Antibody Targeting Factor XI , for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active‐Controlled Phase 2 Study

SHR-2004, ein humanisierter monoklonaler Antikörper gegen Faktor XI, zur Vorbeugung venöser Thromboembolien nach Ovarialkarzinom-Operation: randomisierte, aktiv-kontrollierte Phase-2-Studie

Guangyi Jiang iD, Jie Tang iD, Hongwei Zhao, Keqiang Zhang iD, Jun Gao, Bo Yang, Li Wang, Hongying Yang, Liang Chen, Ruifang An, Hui Zhang, Hualei Bu und 17 weitere

American Journal of Hematology · 2026-11 · 101 (11) · 2776-2785

DOI: 10.1002/ajh.70481 ↗

Auf einen Blick

SHR-2004 wurde nach Ovarialkarzinom-Operation mit Enoxaparin/Rivaroxaban verglichen. VTE traten unter SHR-2004 ähnlich häufig auf; schwere oder klinisch relevante nichtschwere Blutungen waren selten.

Fragestellung

Ist SHR-2004 zur Prävention von VTE nach Ovarialkarzinom-Operation wirksam und sicher im Vergleich zu Enoxaparin/Rivaroxaban?

Methode

Multizentrische, randomisierte, offene explorative Phase-2-Studie an 25 Zentren in China; 1:1-Zuteilung zu SHR-2004 oder Enoxaparin/Rivaroxaban; Beobachtung bis Tag 28.

Ergebnisse

198 Patient:innen erhielten die zugeteilte Behandlung (90 SHR-2004, 108 Enoxaparin/Rivaroxaban). Bei 181 mit Ultraschall: VTE 12,6 % vs. 20,2 %; Differenz −8,4 % (95 %-KI −19,9 bis 3,1). MB/CRNMB: 2,2 % vs. 1,9 %.

Einschränkungen

Explorative Phase-2-Studie; nur 181 Patient:innen mit protokollierter Ultraschallkontrolle; keine ausreichende Power für definitive Aussagen.

Schlussfolgerung der Autor:innen

SHR-2004 zeigte eine mit Enoxaparin/Rivaroxaban vergleichbare Wirksamkeit zur VTE-Prävention nach Ovarialkarzinom-Operation bei ähnlich niedrigem Blutungsrisiko.

Kernaussagen

  • VTE bei 12,6 % unter SHR-2004 und 20,2 % unter Enoxaparin/Rivaroxaban
  • Differenz −8,4 % (95 %-KI −19,9 bis 3,1)
  • MB/CRNMB ähnlich selten: 2,2 % vs. 1,9 %

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, online erschienen am 26.08.2026. Verfasst von Guangyi Jiang und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Ovarian Neoplasms, Postoperative Complications, Venous Thromboembolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This multicenter, randomized, open‐label, exploratory Phase 2 trial assessed SHR‐2004, an anti‐FXI antibody, for venous thromboembolism (VTE) prevention in patients undergoing ovarian cancer surgery—a population at particularly high thrombotic risk conducted at 25 sites in China. Patients with newly diagnosed Stage III–IV or recurrent ovarian cancer scheduled for surgery were randomly assigned (1:1) to receive subcutaneous SHR‐2004 (180 mg on Day 1 and 120 mg on Day 15) or enoxaparin–rivaroxaban (subcutaneous enoxaparin 40 mg once daily during hospitalization, followed by oral rivaroxaban 10 mg once daily after discharge until Day 28). The primary efficacy outcome was the composite of VTE events within 28 days. The primary safety outcome was major bleeding (MB) or clinically relevant nonmajor bleeding (CRNMB) from first dose to 28 days. Between February 19, 2024 and September 17, 2024, 198 patients received assigned treatment (90 with SHR‐2004, 108 with enoxaparin–rivaroxaban) and were included in the safety analysis. Among 181 patients who completed protocol‐mandated ultrasonography, VTE occurred in 11 (12.6%) patients in the SHR‐2004 group and 19 (20.2%) in the enoxaparin–rivaroxaban group (difference −8.4%, 95% CI −19.9 to 3.1) by Day 28. MB/CRNMB rates were similar between groups (SHR‐2004: 2/90 [2.2%]; enoxaparin–rivaroxaban: 2/108 [1.9%]). In this study, SHR‐2004 showed comparable efficacy to enoxaparin–rivaroxaban for preventing postoperative VTE in patients undergoing ovarian cancer surgery, with a similar low risk of MB or CRNMB. The twice‐monthly dosing schedule offers a potential advantage over daily anticoagulation, supporting further investigation in adequately powered Phase 3 trials. Trial Registration: ClinicalTrials.gov identifier: NCT06220123

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedOvarian NeoplasmsPostoperative ComplicationsVenous ThromboembolismAdultAgedFemaleHumansMiddle AgedEnoxaparinHemorrhageRivaroxaban

Stichwörter der Autor:innen

SHR‐2004factor XIovarian cancer surgeryvenous thromboembolism

Substanzen

Antibodies, Monoclonal, HumanizedEnoxaparinRivaroxaban

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
  • Department of Gynecologic Oncology, Hunan Tumor Hospital, Changsha, China.
  • Department of Gynecologic Oncology, Shanxi Provincial Cancer Hospital, Taiyuan, China.
  • Department of Gynecologic Oncology, Jiangxi Cancer Hospital, Nanchang, China.
  • Department of Gynecological Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
  • Department of Gynecological Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.

ORCID-Profile: Guangyi Jiang, Jie Tang, Keqiang Zhang, Jin Li, Ping Zhan, Jianqing Zhu

Förderung

  • Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China

Zitieren

APA

Jiang, G., Tang, J., Zhao, H., Zhang, K., Gao, J., Yang, B., Wang, L., Yang, H., Chen, L., An, R., Zhang, H., Bu, H., Tang, J., Xu, X., Ruan, X., Xia, B., Wang, K., Wei, L., Sheng, X., …, & Zhu, J. (2026). SHR ‐2004, a Humanized Monoclonal Antibody Targeting Factor XI , for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active‐Controlled Phase 2 Study. American Journal of Hematology, 101(11), 2776-2785. https://doi.org/10.1002/ajh.70481

Vancouver

Jiang G, Tang J, Zhao H, Zhang K, Gao J, Yang B, et al. SHR ‐2004, a Humanized Monoclonal Antibody Targeting Factor XI , for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active‐Controlled Phase 2 Study. American Journal of Hematology. 2026;101(11):2776-2785. doi:10.1002/ajh.70481

BibTeX
@article{Jiang2026,
  author = {Jiang, Guangyi and Tang, Jie and Zhao, Hongwei and Zhang, Keqiang and Gao, Jun and Yang, Bo and Wang, Li and Yang, Hongying and Chen, Liang and An, Ruifang and Zhang, Hui and Bu, Hualei and Tang, Junying and Xu, Xizhong and Ruan, Xiaohong and Xia, Bairong and Wang, Ke and Wei, Luwei and Sheng, Xiujie and Guo, Zhe and Chen, Lihong and Wang, Wei and Li, Jin and Wang, Danbo and Zhan, Ping and Guo, Yuhan and Wang, Yuqi and Dong, Yanli and Zhu, Jianqing},
  title = {SHR ‐2004, a Humanized Monoclonal Antibody Targeting Factor XI , for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active‐Controlled Phase 2 Study},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {11},
  pages = {2776--2785},
  doi = {10.1002/ajh.70481}
}
Kostenlos starten →